Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347123 · ClinicalTrials.gov registry record · Phase 1
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03347123 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 11 participants.
The verdict
NCT03347123, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.
Interventions
- DRUG Epacadostat
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Lirilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-03-21 |
| Est. Completion | 2021-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03347123
The ClinicalTrials.gov registry entry for NCT03347123 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Epacadostat is the first listed.
NCT03347123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03347123 about?
NCT03347123 is a clinical study titled "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)". The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.
What is the current status of trial NCT03347123?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2018-03-21. Estimated completion is 2021-01-29.
What interventions are being tested in trial NCT03347123?
The interventions under investigation include: Epacadostat (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Lirilumab (DRUG).
Who is sponsoring clinical trial NCT03347123?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.